Classification of Medicines
Pursuant to section 106(1) of the Medicines Act 1981, I, Dr Don Mackie, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health, acting under delegated authority, hereby declare the following:
Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological or mineral sources.
Unless specific reference is made otherwise, every reference applies also to medicines that are:
Unless specific reference is made otherwise, every reference to a medicine applies:
Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise.
Prescription Medicines
Aloracetam
Aniracetam
Azelastine; except when specified elsewhere in this notice
Bilastine; except when specified elsewhere in this notice
Bosutinib
Brentuximab vedotin
Brivaracetam (and its stereoisomers)
Carglumic acid
Cebaracetam (and its stereoisomers)
Coluracetam
Dimiracetam (and its stereoisomers)
Doliracetam (and its stereoisomers)
Dupracetam
Etiracetam
Elosulfase alfa
Fasoracetam (and its stereoisomers)
Fomepizole
Fonturacetam (and its stereoisomers)
Idarucizumab
Idelalisib
Imuracetam
Ketoprofen; except when specified elsewhere in this notice
Molracetam
Nebracetam (and its stereoisomers)
Nefiracetam
Nepidermin
Nicoracetam
Noopept (and its stereoisomers)
Otilonium bromide
Oxiracetam (and its stereoisomers)
Paritaprevir
Peginterferon beta-1a
Pembrolizumab
Pirfenidone
Piperacetam
Pramiracetam
Ranolazine
Recombinant human Epidermal Growth Factor
Rolipram (and its stereoisomers)
Rolziracetam
Secukinumab
Seletracetam (and its stereoisomers)
Suvorexant
Schedule 2
Restricted Medicines
Ketoprofen; in solid dose form containing 25 milligrams or less per dose form in packs of not more than 30 capsules or tablets
Schedule 3
Pharmacy-only Medicines
Azelastine; in preparations for nasal use containing 0.15% azelastine hydrochloride or less; in topical eye preparations containing 0.05% or less
Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjunctivitis (seasonal and perennial) and urticaria when sold in a pack containing not more than 30 dosage units
Macrogols; in preparations for oral use as a liquid concentrate for laxative use
Please note that the following medicines are now available for general sale.
Efmoroctocog alfa
Simoctocog alfa
Dated this 10th day of August 2015.
Dr DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health.